Get Involved

The molecular investigation of unexplained anaemias and related congenital anaemias

Contact phone number: Dr Peter Carey/Dr Jonathan Wallis 0191 2824743

Why is this study important? 

Some rare types of anaemia (lack of blood) are inherited (passed from parent to child in genes). Some causes are known, while others are waiting to be discovered.

What is the aim of this study? 

The aim is to find the genes that cause these anaemias. This could help to diagnose patients more quickly and find new treatments.

What do people in this study have to do? 

The study is for patients who have anaemia for which no cause has been found. Checks for faulty genes would be done from blood or saliva. If you have had a bone marrow test done, we will ask if we may have any left over samples. We would collect relevant information about your anaemia from your medical notes.

What are the risks and benefits for participants? 

It is possible we could stumble upon a faulty gene, unrelated to anaemia, which could affect your health. You can choose whether you would want to know about this. You will not be recognisable in any document published by us.  You will be able to tell us whether you want any information on the results of our research by ticking a box on the following consent form.

For further information about this study please follow link

Recruitment to this study is due to end:

Nov 2018

A summary of the study findings should be available by:

We hope to publish our research results in a scientific journal, readable by physicians around the world.

Clinical Trials in Haematology

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

The study is for patients with cancer who have been on a blood-thinner for a new clot for less than 3 days (and fit other criteria).

UK Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry

This is a registry study that is aiming to recruit hundreds of individuals with ITP within the UK.

UK Childhood ITP Registry

The main aims of this project are to try and understand why some children with a low platelet count bleed, when there is a need for treatment and how having ITP impacts on the quality of life on the child and family.

The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (TTP Registry)

The information from this study may help us to increase our understanding and improve future treatment for patients with TTP.

The molecular investigation of unexplained anaemias and related congenital anaemias

The study is for patients who have anaemia for which no cause has been found.

Einstein Junior study (Phase II)

The aim is see if rivaroxaban is as good at treating and preventing recurrence of blood clots in children as standard treatment (warfarin or heparin). The study will also see if rivaroxaban causes less or more bleeding than standard treatment.

Einstein Junior study (Phase III)

Options for the treatment of thrombosis (blood clots) in children are limited. Anticoagulant (blood-thinning) therapy can either be with a tablet called warfarin which needs monitoring with regular blood tests, or a daily injection of heparin. Rivaroxaban is an anticoagulant that can be given as a tablet or syrup and does not need monitoring.

ECHO: Expanding Communications on Haemophilia-A Outcomes

A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and clinical impact of Haemophilia A and its treatment in patients with moderate to severe Haemophilia A.


This study will observe feelings when discussing PK guided dosing with patients in the clinic & the process of discussing their own, personal PK profile after a brief educational session.

Latest news from PPI

View all